1. Generics Bulletin
  2. >>Business
  3. >>Deals

Teva Strikes Two Settlements Over ‘Pay-For-Delay’ Agreements

 
• By Akriti Seth

A California Court has secured four major settlements worth $70m with pharmaceutical companies over allegations of entering into collusive pay-for-delay agreements, including two with Teva.

Dollar_Gavel
Pharma companies strike settlements worth $70m for delaying competition and increasing drug prices • Source: Shutterstock

California attorney general Xavier Becerra has announced settlements with firms including Teva that are worth nearly $70m, as part of action taken over so-called ‘pay for delay’ deals that delayed competition and increased drug prices. The companies had been accused of entering into collusive agreements that illegally delayed affordable prescription drugs from entering the market.

As per the statement issued by the California government, out of the two settlements agreed with Teva, the first settlement...

More from Deals

Beyond ‘Vanilla’ Generics: How Lupin Is Evolving To Stay Ahead Of The UK Competition

 
• By Dave Wallace

As UK players face increasing competitive pressures on “vanilla” generics – including potential new market entrants from China – Ben Ellis, Lupin’s UK and Ireland general manager, explains how the company is focusing on more complex opportunities that require a hybrid generic and branded mindset.

Teva Continues Push Beyond Generics in Fosun Immunotherapy Tie-Up

 
• By Dean Rudge

Teva has agreed to partner with China’s Fosun Pharma to develop TEV-56278, a targeted cancer immunotherapy, marking the next step in its continued pivot from its generics roots toward complex biologics and innovative oncology treatments. The deal covers key Asian markets, including mainland China, w

Lupin Looks To Expand In China With Respiratory Alliance

 
• By Dave Wallace

Lupin is planning to expand its footprint in China through a deal for a tiotropium dry powder inhaler with local player Sino Universal Pharmaceuticals.

Welch Heads Up Par Ahead Of Planned Spin-Off After Endo-Mallinckrodt Merger

 
• By Dave Wallace

As Endo and Mallinckrodt continue to work towards consummating the merger they announced earlier this year, the pair have revealed further organizational details of their combined generics and sterile injectables business, which is set to be spun off after the merger is complete.

More from Business

Lupin Looks To Expand In China With Respiratory Alliance

 
• By Dave Wallace

Lupin is planning to expand its footprint in China through a deal for a tiotropium dry powder inhaler with local player Sino Universal Pharmaceuticals.

Welch Heads Up Par Ahead Of Planned Spin-Off After Endo-Mallinckrodt Merger

 
• By Dave Wallace

As Endo and Mallinckrodt continue to work towards consummating the merger they announced earlier this year, the pair have revealed further organizational details of their combined generics and sterile injectables business, which is set to be spun off after the merger is complete.

Replacements Named As Eder Leaves Stada And Medicines For Europe

 
• By Dave Wallace

Stephan Eder has left Stada and stepped down as president of Medicines for Europe, with the company announcing plans for his replacement and the association naming Polpharma CEO Markus Sieger as the association’s new interim president.